ESPR insider trading
NasdaqGM HealthcareEsperion Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Company website: www.esperion.com
ESPR insider activity at a glance
FilingIQ tracks 304 insider transactions for ESPR in filings since Feb 20, 2015. The most recent transaction is dated Jul 13, 2026.
Across the full history, 47 open-market purchases
and 120 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ESPR insider trades is 51.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ESPR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ESPR?
- FilingIQ tracks 304 Form 4 insider transactions for ESPR (Esperion Therapeutics, Inc.), covering filings from Feb 20, 2015 onwards. 9 of those are dated within the last 90 days.
- Are ESPR insiders net buyers or net sellers?
- Across the full Form 4 history for ESPR, 47 transactions (15%) were open-market purchases and 120 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ESPR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ESPR in?
- Esperion Therapeutics, Inc. (ESPR) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $837.92M.
Methodology & sources
Every ESPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.